Form 4 Filing for Karlin Daniel

Karlin Daniel, Chief Medical Officer of Definium Therapeutics, Inc. (DFTX), acquired 200,000 shares of common stock on September 14, 2026. These shares represent the third tranche of performance share units granted on March 12, 2025, and are subject to vesting based on continued employment through March 12, 2028. The acquisition was a grant with a transaction price of $0.00 per share. Following this transaction, Daniel owns 803,699 shares. The filing also notes that 417 shares were acquired under the company's Employee Share Purchase Plan on August 17, 2026.